Capricor Therapeutics (CAPR) Q1 2026 earnings summary

Executive summary

• Deramiocel's Biologics License Application is under active FDA review with a PDUFA target date of August 22, 2026, following positive HOPE-3 phase III trial data.

• Legal action has been initiated to rescind the U.S. distribution agreement with NS Pharma/Nippon Shinyaku due to a flawed pricing structure, aiming for independent commercialization.

• Commercial readiness efforts have accelerated, including hiring key leadership and preparing manufacturing and distribution infrastructure for an independent launch.

• No products are approved or commercial revenue recognized to date; operations are funded by equity, grants, and collaborations.

• Focus remains on cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with unmet needs.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $278.6 million as of March 31, 2026.

• No revenue recognized for Q1 2026 or Q1 2025.

• Q1 2026 operating expenses were $36.8 million, up from $25 million in Q1 2025, driven by clinical, regulatory, and manufacturing investments.

• Net loss for Q1 2026 was $33.9 million ($0.59/share), compared to $24.4 million ($0.53/share) in Q1 2025.

• Comprehensive loss for Q1 2026 was $34.5 million, compared to $23.6 million in Q1 2025.

Outlook and guidance

• Anticipates FDA approval decision for Deramiocel in August 2026 and expects to be eligible for a priority review voucher upon approval.

• Plans to launch Deramiocel independently, pending court decision, with commercial infrastructure and manufacturing capacity being scaled.

• Expects to spend $100–$125 million in 2026 on Deramiocel, mainly for manufacturing and commercialization prep.

• Expansion into Becker muscular dystrophy and younger DMD patients planned post-PDUFA, with global regulatory discussions scheduled.

• Exosome platform development spend projected at $7–$10 million for 2026.